Otonomy Investor Relations Material
Latest events
Q2 2022
Otonomy
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Otonomy Inc
Access all reports
Otonomy, Inc. is a biopharmaceutical company, focuses on the development of therapeutics for neurotology in the United States. The company's lead product candidate is OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine that is being developed to treat tinnitus. In addition, the company has two Phase II clinical trials for OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor for the treatment of speech in noise hearing difficulties and repair cochlear synaptopathy remodeling caused by acute hearing loss.
Latest articles
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F1882x1059%2F7e17876154%2Fbirkin.png&w=3840&q=75)
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2688x1512%2F8365aa8316%2Ftop-10-largest-semiconductor-companies.png&w=3840&q=75)
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F135c0e3f6b%2Fthe-rise-of-nubank.png&w=3840&q=75)
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
OTIC
Country
đșđž United States